Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside other inflammatory conditions.

The Washington Post reported on Friday that state Medicaid programs and Medicare Part D insurance plans will be able to ...

Peptide injections promising rapid recovery, muscle growth, and fat loss are gaining popularity among middle-aged men—but ...

Shares in European pharmaceutical firms slumped on Friday following a threat by President Donald Trump to punish them if they don't lower prices for medicines in the United States.